This volume, a state-of-the-art review of early phase clinical trials for cancer immunotherapy, discusses biomarker selection, combinatorial strategies and their safety or toxicity, determination of Phase 2 dosing, endpoints in the setting of radiographic pseudoprogression, histology selection, and novel immunotherapeutics as they relate to early phase cancer immunotherapy.
Reihe
Auflage
Softcover reprint of the original 1st ed. 2018
Sprache
Verlagsort
Verlagsgruppe
Springer International Publishing
Zielgruppe
Illustrationen
9
15 farbige Abbildungen, 9 s/w Abbildungen
XI, 331 p. 24 illus., 15 illus. in color.
Maße
Höhe: 235 mm
Breite: 155 mm
Dicke: 19 mm
Gewicht
ISBN-13
978-3-319-87628-3 (9783319876283)
DOI
10.1007/978-3-319-63757-0
Schweitzer Klassifikation
Razelle Kurzrock, MD, is Senior Deputy Director for Clinical Science, Chief, Division of Hematology & Oncology, Murray Professor of Medicine, Director, Center for Personalized Cancer Therapy & Clinical Trials Office, University of California, San Diego.
Sandip Patel, MD, is Assistant Professor, Cancer Immunotherapy Program, Experimental Therapeutics (Phase 1 Program), Thoracic Oncology, Division of Hematology & Oncology and Center for Personalized Cancer Therapy, UC San Diego Moores Cancer Center.
